leisure time -WSS

leisure time

author：knowledge 2025-09-28 23:48:38 - browse：9

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： FDA investigates CAR

knowledge

WSS

Rep. Raul Ruiz on the physician shortage and more

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Diagnostic tests are hitting their mathematical limits

Ask STAT: What do you want to know about ChatGPT in medicine?

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Donald Trump's relentless attacks on special counsel Jack Smith

explore

leisure time

Wikipedia

Jerome Adams on the need for new antivirals for Covid

With clinical trial data readouts, here's how to spot spin

Bright Health sells Medicare Advantage business to Molina

#NeedHerScience: shining a light on gender disparities in medicine

Duchenne breakthrough therapy leaves behind pioneering families

The science behind Janet Jackson's pregnancy at 49

23andMe had bad news about my health. I wish a person had delivered it

With FDA staff opposed to Sarepta therapy, top official intervened

FDA approval of Sarepta Duchenne genetic therapy gives me hope

30 years of 'Listening to Prozac'

focus

What to do when lifesaving products contribute to climate change

30 years of 'Listening to Prozac'

Flagship Pioneering launches a new biotech in two countries

ReNAgade cuts staff seven months after raising $300 million

The EPA's new lead rule: How one expert crunched the numbers

Cloning humans is technically possible. It's curious no one has tried

leisure time

focus

knowledge

hotspot